Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.
Cardiome Pharma Corp. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Response Biomedical Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avellino is a global leader in precision medicine, focused on innovative genetic diagnostics, gene therapies, and genetic data for modern eyecare practices.
Macherey-Nagel is a Easton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.